MSL Manager (职位编号:01761433)
和记黄埔医药(上海)有限公司
- 公司规模:150-500人
- 公司性质:外资(非欧美)
- 公司行业:制药/生物工程
职位信息
- 发布日期:2022-06-24
- 工作地点:上海-浦东新区
- 工作经验:8-9年经验
- 学历要求:硕士
- 职位月薪:3-4万
- 职位类别:医学顾问
职位描述
PRIMARY FUNCTION
Provide medical support to HMP throughout all products lifecycles and manage MSL team.
MAJOR RESPONSIBILITIES AND DUTIES
1.MSL manager provides medical support to products lifecycle management by
? Exchange and dissemination of scientific, educational, and research related information.
? Organize / support / participate Medical activities and Advisory Boards.
? Collect ITT ideas and facilitate ITT & phase IV set-up.
? Contribute to the development of Medical Strategies by KOL insights feedback.
? Communicate and track the study progress and completion.
? Provide scientific training to the corresponding commercial team.
2 .To be responsible for the team development, including recruiting, training, assessing and developing of individual
? To recruit new staff based on the business needs and position qualification
? Providing training and coaching MSL team members for developing people
? Leading and planning for MSL team members to implement MSL function in regular base under medical affairs framework
? Leading and coordinating the good cooperation of MSL team members with other functions.
QUALIFICATIONS
? Master degree or above in Clinical Medicine.
? 2+ years’ experience in industry as senior medical scientific liaisons. Team managerial experiences are preferred.
? Have strong leadership.
? Direct experience in developing or managing clinical trials.
? Understanding of policy/healthcare country regulations and proven ability to communicate company policies.
? Fluent in spoken and written English.
Internal-External Relations
Internal: staffs within C&R department
External: Investigators and other relevant persons in hospitals or institutes
Provide medical support to HMP throughout all products lifecycles and manage MSL team.
MAJOR RESPONSIBILITIES AND DUTIES
1.MSL manager provides medical support to products lifecycle management by
? Exchange and dissemination of scientific, educational, and research related information.
? Organize / support / participate Medical activities and Advisory Boards.
? Collect ITT ideas and facilitate ITT & phase IV set-up.
? Contribute to the development of Medical Strategies by KOL insights feedback.
? Communicate and track the study progress and completion.
? Provide scientific training to the corresponding commercial team.
2 .To be responsible for the team development, including recruiting, training, assessing and developing of individual
? To recruit new staff based on the business needs and position qualification
? Providing training and coaching MSL team members for developing people
? Leading and planning for MSL team members to implement MSL function in regular base under medical affairs framework
? Leading and coordinating the good cooperation of MSL team members with other functions.
QUALIFICATIONS
? Master degree or above in Clinical Medicine.
? 2+ years’ experience in industry as senior medical scientific liaisons. Team managerial experiences are preferred.
? Have strong leadership.
? Direct experience in developing or managing clinical trials.
? Understanding of policy/healthcare country regulations and proven ability to communicate company policies.
? Fluent in spoken and written English.
Internal-External Relations
Internal: staffs within C&R department
External: Investigators and other relevant persons in hospitals or institutes
职能类别:医学顾问
公司介绍
和黄中国医药科技有限公司(简称“ 和黄医药 ”或“ Chi-Med ”)(纳斯达克 / 伦交所:HCM)是一家创新型生物医药公司,在过去20年间致力于发现和全球开发治疗癌症和自身免疫性疾病的靶向药物和免疫疗法。目前,和黄医药共有8个抗癌类候选药物正在全球开发中,并在中国本土市场拥有广泛的商业网络。
和黄医药成立于2002年,为在纽约和伦敦两地上市的和黄中国医药科技有限公司(纳斯达克/伦交所: HCM)旗下专注于新药研发业务的子公司, 研发中心坐落在上海浦东张江高科技园区,海外临床开发及注册中心位于美国新泽西,具有完备的研发平台和GMP生产基地。管理团队成员均有在知名跨国医药和生物医药企业工作的经历,参与了多个全球新药研发;公司目前有500余位来自海内外,拥有丰富新药研发经验的科研人员,8大临床在研药物、 30多项临床试验在全球开展。
和黄医药是一家致力于创新药物研发的生物医药公司,专注于发现和开发治疗癌症和自身免疫性疾病的靶向药物和免疫疗法。 自主研发的抗肿瘤新药呋喹替尼已于2018年9月获国家药品监督管理局批准上市,并于2019年11月获纳入国家医保药品目录。公司的其他候选药物,如索凡替尼、沃利替尼等,也已进入后期开发,有望在2020及2021年上市。
和黄医药成立于2002年,为在纽约和伦敦两地上市的和黄中国医药科技有限公司(纳斯达克/伦交所: HCM)旗下专注于新药研发业务的子公司, 研发中心坐落在上海浦东张江高科技园区,海外临床开发及注册中心位于美国新泽西,具有完备的研发平台和GMP生产基地。管理团队成员均有在知名跨国医药和生物医药企业工作的经历,参与了多个全球新药研发;公司目前有500余位来自海内外,拥有丰富新药研发经验的科研人员,8大临床在研药物、 30多项临床试验在全球开展。
和黄医药是一家致力于创新药物研发的生物医药公司,专注于发现和开发治疗癌症和自身免疫性疾病的靶向药物和免疫疗法。 自主研发的抗肿瘤新药呋喹替尼已于2018年9月获国家药品监督管理局批准上市,并于2019年11月获纳入国家医保药品目录。公司的其他候选药物,如索凡替尼、沃利替尼等,也已进入后期开发,有望在2020及2021年上市。
联系方式
- Email:hr@hmplglobal.com
- 公司地址:和记黄埔医药创新药生产基地